Treatment of Reactivated Ocular Toxoplasmosis in an Immunocompromised State
When reactivated ocular toxoplasmosis occurs in a patient with an immunocompromised state, management differs in key respects from the approach used in immunocompetent patients. Both treatment duration and the role of adjunctive agents require specific consideration in this population.
Clinical Scenario
This protocol addresses reactivated ocular toxoplasmosis in patients who are immunocompromised. Impaired host immunity alters both the risk of severe disease and the way treatment must be structured, requiring a protocol distinct from standard management.
Treatment Approach
Antimicrobial combination therapy forms the basis of treatment. In the immunocompromised patient, the treatment course is extended compared to immunocompetent management, and systemic corticosteroids are avoided. The specific regimen options, agents, and complete treatment algorithm are detailed in the full protocol.
Treatment Goal
Complete resolution of the ocular lesions.
References
DOI: 10.1007/s10792-021-01994-9
- Immunocompromised patients are treated with the antimicrobial regimens described above, for 6 or more weeks.
- Systemic corticosteroids are usually avoided in immunocompromised patients.